Under pressure, Biogen outlines ambitious diversity goals for Aduhelm study — but the Medicare fight is still on
Biogen, facing renewed criticism for a lack of diversity in its Alzheimer’s clinical trials, announced on Thursday a new commitment: At least 18% of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
